Plasmalogen- and ginkgo biloba extract-containing composition

Abstract

To provide a method that enables long-term stable preservation of plasmalogen when plasmalogen is used in combination with ginkgo biloba extract.SOLUTION: A composition comprising plasmalogen, ginkgo biloba extract, and arginine and / or lysine, wherein the pH upon tenfold dilution with ion-exchanged water is in the range of 3.4 to 5.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to a composition containing plasmalogen and ginkgo leaf extract, etc. [Background technology]

[0002] Plasmalogen (sometimes referred to as Pls in this specification) is a type of ether-type glycerophospholipid with a vinyl ether bond at position 1 of the glycerol backbone. Plasmalogens are widely distributed in animals and certain anaerobic microorganisms, and in humans, they are known to be present in large amounts in the nervous, cardiovascular, and immune systems. Furthermore, plasmalogens are known to be present in cell nuclei and synaptic clefts, suggesting that plasmalogens play a wide range of roles in neural activity.

[0003] To date, functions of plasmalogens have been revealed, such as brain neurogenesis (Patent Document 1), anti-inflammatory effects in the central nervous system (Patent Document 2), and enhancement of healthy learning and memory abilities (Patent Document 3). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2011 / 083827 [Patent Document 2] International Publication No. 2012 / 039472 [Patent Document 3] Japanese Patent Application Laid-Open No. 2016-210696 [Patent Document 4] Japanese Patent Application Publication No. 2019-143054 [Patent Document 5] Japanese Patent Application Publication No. 2019-142818 [Patent Document 6] Japanese Patent Application Publication No. 2019-140983 [Patent Document 7] International Publication No. 2020 / 009173 Summary of the Invention [Problem to be solved by the invention]

[0005] Because plasmalogen has been reported to have the above-mentioned functions, it is expected to be particularly effective in preventing and improving dementia. Furthermore, ginkgo biloba extract has also been reported to have the effect of preventing and improving dementia, so the development of a product that combines these two is desirable. However, the fact that plasmalogen is decomposed when combined with ginkgo biloba extract has been an issue in product development. [Means for solving the problem]

[0006] The present inventors have found that the stability of plasmalogen is increased by using arginine and / or lysine when plasmalogen is used in combination with ginkgo leaf extract, and have made further improvements.

[0007] The present disclosure encompasses, for example, the subject matter described in the following sections: Section 1. Plasmalogen, Ginkgo biloba extract, and containing arginine and / or lysine, A composition having a pH of 3.4 to 5 when diluted 10 times with ion-exchanged water. Section 2. Item 1. The composition according to item 1, wherein the plasmalogen intake per meal is 0.5 to 2.0 mg. Section 3. Item 3. The composition according to Item 1 or 2, wherein the mass ratio of the plasmalogen to the ginkgo leaf extract is 1:8 to 1:600. Section 4. Item 4. The composition according to any one of Items 1 to 3, containing 0.028 to 3.3% by mass of plasmalogen. Section 5. Item 1. The composition according to any one of items 1 to 4 or 2, comprising 4.44 to 75% by mass of ginkgo biloba extract. Section 6. Item 6. The composition according to any one of items 1 to 5, which is a liquid composition. [Effects of the Invention]

[0008] A method is provided for stably storing plasmalogen for a long period of time, even when plasmalogen and ginkgo leaf extract are used in combination. [Brief explanation of the drawings]

[0009] [Figure 1] 1 shows the results of stability evaluation of a composition containing Pls and ginkgo leaf extract. (A) shows the change in Pls concentration, and (B) shows the change in the blending ratio. [Figure 2] 1 shows the results of stability evaluation of Pls-containing compositions. (A) shows the change in Pls concentration, and (B) shows the change in the blending ratio. DETAILED DESCRIPTION OF THE INVENTION

[0010] Each embodiment included in the present disclosure will be described in further detail below. The composition encompassed by the present disclosure contains a plasmalogen, a ginkgo biloba extract, and arginine and / or lysine. In this specification, the composition may be referred to as the "plasmalogen- and ginkgo biloba extract-containing composition of the present disclosure."

[0011] Plasmalogens are generally glycerophospholipids with a long-chain alkenyl group attached via a vinyl ether bond to the sn-1 position of the glycerol backbone. The general formula for plasmalogens is shown below.

[0012] [ka]

[0013] [In the formula, R 1 and R 2 represents an aliphatic hydrocarbon group. 1R is usually an aliphatic hydrocarbon group having 1 to 20 carbon atoms (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20), and examples thereof include a dodecyl group, a tetradecyl group, a hexadecyl group, an octadecyl group, and an icosanyl group. 2 is usually an aliphatic hydrocarbon group derived from a fatty acid residue, and examples thereof include an octadecadienoyl group, an octadecatrienoyl group, an icosatetraenoyl group, a docosatetraenoyl group, a docosapentaenoyl group, and a docosahexaenoyl group. In the formula, X represents a polar group. X is preferably ethanolamine, choline, serine, inositol, or glycerol.

[0014] In particular, ethanolamine plasmalogens, in which X is ethanolamine in the above formula, and choline plasmalogens, in which X is choline, are plasmalogens that exist widely in nature, and are also preferred as plasmalogens for use in the present disclosure.

[0015] Plasmalogens can be, for example, synthetic products, extracts, etc. Among these, those extracted from biological tissues are preferred. Biological tissue refers to tissues in an organism that contain plasmalogen. Examples of organisms used to extract plasmalogen include animals and microorganisms. Anaerobic bacteria are preferred as microorganisms, and bacteria of the Acidaminococcaceae family, which are enterobacteria, are particularly preferred. In the case of bacteria, the "biological tissue" refers to the bacteria themselves. Preferred animals include birds, mammals, fish, shellfish, etc. From the standpoint of supply stability and safety, livestock and poultry are preferred as mammals, such as cows, pigs, horses, sheep, goats, and birds. In the case of mammals, tissues containing plasmalogen mainly include the skin, brain, intestines, heart, and reproductive organs, and plasmalogen can be extracted from these tissues. Examples of birds include chickens, domestic ducks, quails, wild ducks, pheasants, and turkeys. Considering ease of availability, cost, and reluctance to eat them, chickens are particularly preferred. The poultry tissue is not particularly limited, but examples thereof include poultry meat (particularly poultry breast meat), poultry skin, and poultry internal organs. Examples of shellfish include scallops. Two or more different tissues from one or more organisms may be combined.

[0016] It is particularly preferable to use plasmalogen extracted from bird tissue as the plasmalogen extracted from biological tissue. Among them, birds (poultry) that have traditionally been used for food are preferred because their safety has been confirmed and stable supply is easy. Among them, chicken is the most suitable.

[0017] The method for extracting plasmalogen from biological tissue is not particularly limited as long as plasmalogen can be extracted (and purified as necessary). For example, it can be extracted by a known method or a method that can be easily conceived from a known method. Examples include the methods described in Patent Document 3 (JP 2016-210696 A), Patent Document 4 (JP 2019-143054 A), Patent Document 5 (JP 2019-142818 A), Patent Document 6 (JP 2019-140983 A), Patent Document 7 (WO 2020 / 009173 A), etc. As described in the document, the plasmalogen extract may be, for example, a purified product or a concentrated product. Furthermore, as described in the document, the plasmalogen extract may be, for example, a solidified product (for example, a dried product or powder). Furthermore, commercially available plasmalogens may be purchased and used.

[0018] The ginkgo leaf extract used in the present disclosure may be, for example, an extract or a commercially available product.

[0019] Ginkgo biloba (scientific name: Ginkgo biloba), which is used as a raw material for extracting ginkgo biloba extract, is a deciduous tree belonging to the genus Ginkgo in the family Ginkgoaceae. The method for obtaining ginkgo biloba is not particularly limited, and for example, it may be collected from nature or commercially available.

[0020] Ginkgo biloba extract can be easily obtained by a method commonly used for plant extraction, such as immersing ginkgo leaves used as the extraction raw material in an extraction solvent, stirring as necessary to elute soluble components, and then filtering to remove the extraction residue to obtain the ginkgo biloba extract.

[0021] The size of ginkgo leaves used as the extraction raw material is not particularly limited, and may be, for example, the size as collected, cut to a desired size, or pulverized (powdered) size.

[0022] The state of ginkgo leaves used as the extraction raw material is not particularly limited. For example, they may be in the state as collected, dried, crushed, squeezed juice, etc. Among these, the dried state is preferred.

[0023] The method for drying ginkgo leaves is not particularly limited, and examples thereof include drying in the sun and drying using a dryer.

[0024] The method for pulverizing the ginkgo leaves is not particularly limited, and examples thereof include pulverization using a mixer, sugar mill, power mill, jet mill, impact pulverizer, etc.

[0025] The method for extracting juice from ginkgo leaves is not particularly limited, and examples thereof include squeezing.

[0026] The extraction solvent for ginkgo leaf extract is not particularly limited, and examples thereof include water, a hydrophilic solvent, and a mixture thereof.

[0027] Examples of water include pure water, tap water, well water, mineral water, hot spring water, spring water, fresh water, purified water, hot water, ion-exchanged water, saline solution, phosphate buffer solution, phosphate buffered saline solution, etc. These may be used alone or in combination of two or more.

[0028] Examples of hydrophilic solvents include lower alcohols having 1 to 5 carbon atoms, such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones, such as acetone and methyl ethyl ketone; and polyhydric alcohols having 2 to 5 carbon atoms, such as 1,3-butylene glycol, propylene glycol, and glycerin. These may be used alone or in combination of two or more.

[0029] The mixed solvent of water and a hydrophilic solvent is not particularly limited. When a lower alcohol is used as the hydrophilic solvent, the mixed solvent of water and the hydrophilic solvent preferably contains 1 to 90 parts by mass of the hydrophilic solvent per 10 parts by mass of water. The upper or lower limit of this range may be, for example, 20, 30, 40, 50, 60, 70, or 80 parts by mass. More specifically, it may be, for example, 20 to 80 parts by mass. When a lower aliphatic ketone is used as the hydrophilic solvent, the mixed solvent of water and hydrophilic solvent preferably contains 1 to 40 parts by mass of hydrophilic solvent per 10 parts by mass of water. The upper or lower limit of this range may be, for example, 5, 10, 15, 20, 25, 30, or 35 parts by mass. More specifically, it may be, for example, 5 to 35 parts by mass. When a polyhydric alcohol is used as the hydrophilic solvent, the mixed solvent of water and the hydrophilic solvent preferably contains 1 to 90 parts by mass of the hydrophilic solvent per 10 parts by mass of water. The upper or lower limit of this range may be, for example, 20, 30, 40, 50, 60, 70, or 80 parts by mass. More specifically, it may be, for example, 20 to 80 parts by mass. These may be used alone or in combination of two or more.

[0030] Among these, a mixed solvent of water and ethanol (hydrous ethanol) is preferred as the extraction solvent for ginkgo leaf extract from the viewpoints of safety and ease of handling. When aqueous ethanol is used as the extraction solvent, the concentration of ethanol is not particularly limited, but is preferably 50% by mass or more, and more preferably 70% by mass or more, for example.

[0031] The amount of extraction solvent used is not particularly limited, and can be, for example, about 5 to 15 times (by mass) the amount of ginkgo leaves used as the extraction raw material.

[0032] The extraction conditions for ginkgo leaf extract (extraction time, extraction temperature, atmospheric conditions such as pressure, etc.) are not particularly limited, and any known method can be selected. The extraction time for eluting the soluble components of the ginkgo leaf extract can be, for example, about 30 minutes to 4 hours, or about 30 minutes to 2 hours. The temperature of the extraction solvent is preferably room temperature or a temperature not higher than the boiling point of the solvent used. When a mixed solvent of water and ethanol is used as the extraction solvent, extraction is preferably carried out at 40°C to 80°C for about 30 minutes to 4 hours.

[0033] The ginkgo biloba extract may be, for example, a crude product, a purified product, a concentrate, a diluted product, a dried product, etc. Alternatively, the ginkgo biloba extract may be prepared by mixing or dissolving a dried ginkgo biloba extract in a solvent such as water, a hydrophilic solvent, or a mixture thereof.

[0034] The purification method of ginkgo biloba extract is not particularly limited. Examples include chromatography such as partition chromatography, adsorption chromatography, ion exchange chromatography, and size exclusion chromatography, liquid-liquid partition extraction, and membrane separation. These purification methods may be used alone or in combination. Among these, ginkgo biloba extract is preferably purified using an adsorption resin.

[0035] The adsorption resin is not particularly limited and can be appropriately selected depending on the purpose, but aromatic or aromatic-modified adsorption resins are preferred. Specific examples of adsorption resins include Diaion HP20, Diaion HP21, Sepabeads SP825L, Sepabeads SP850, Sepabeads SP207 (all manufactured by Mitsubishi Chemical Corporation), Amberlite XAD-2, Amberlite XAD4, Amberlite XAD7 (all manufactured by Organo Corporation), and the like.

[0036] An example of a commercially available ginkgo leaf extract is Ginkgo Leaf Extract C (manufactured by Maruzen Pharmaceutical Co., Ltd.).

[0037] The ginkgo leaf extract may contain, as active ingredients, flavonoid glycosides such as quercetin, isorhamnetin, and kaempferol, and terpene lactones such as ginkgolide and bilobalide.

[0038] The plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure contains arginine and / or lysine. These may be used alone or in combination of two or more. Among these, arginine is preferred.

[0039] The plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure may be, for example, a liquid composition (e.g., solution, suspension, etc.) or a solid composition (e.g., powder, granules, etc.). Of these, a liquid composition is preferred.

[0040] Furthermore, the plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure preferably has a pH of about 3.4 to 5 when diluted 10 times with ion-exchanged water. The pH is measured at 25°C using a pH meter. The 10-fold dilution here refers to a 10-fold dilution by mass. The upper or lower limit of the pH range may be, for example, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, or 4.9. Specifically, it may be about 3.4 to 4.5, or about 3.5 to 4. As shown in the examples described below, plasmalogen-containing compositions that do not contain ginkgo leaf extract are highly stable when the pH is approximately 7.0 when diluted 10 times with ion-exchanged water, and when the pH is within the above range, the plasmalogen is decomposed.However, when the pH of the plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure is within the above range when diluted 10 times with ion-exchanged water, the stability of the plasmalogen can be increased even when plasmalogen and ginkgo leaf extract are used in combination.

[0041] The content of each ingredient in the plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure can be set appropriately within a range that does not impair the effects of the present disclosure. The plasmalogen content in the plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure may be, for example, about 0.028 to 3.3% by mass. The upper or lower limit of this range may be, for example, about 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, or 3.2% by mass. Specifically, it may be about 0.03 to 1.4% by mass.

[0042] The content of ginkgo leaf extract in the plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure can be, for example, about 4.44 to 75% by mass. The upper or lower limit of this range may be, for example, about 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, or 70% by mass. Specifically, it may be about 5 to 70% by mass.

[0043] In the plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure, the mass ratio of plasmalogen to ginkgo leaf extract can be, for example, about 8 to 600 parts by mass of ginkgo leaf extract per 1 part by mass of plasmalogen. The upper or lower limit of this range can be, for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, or 550 parts by mass. Specifically, it can be about 10 to 550 parts by mass, or about 50 to 200 parts by mass.

[0044] In the plasmalogen and ginkgo leaf extract-containing composition of the present disclosure, arginine and / or lysine may be blended so that the pH of the plasmalogen and ginkgo leaf extract-containing composition of the present disclosure when diluted 10 times with ion-exchanged water is 3.4 to 5. When arginine is used, it may be contained in an amount of, for example, about 0.01 to 6% by mass. The upper or lower limit of this range may be, for example, about 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, or 5.5% by mass. Specifically, it may be about 0.02 to 5.5% by mass. When lysine is used, it may be contained in an amount of, for example, about 0.01 to 5.0% by mass. The upper or lower limit of this range may be, for example, about 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, or 4.5% by mass. Specifically, it may be about 0.02 to 4.5% by mass. When arginine and lysine are used, the total content of arginine and lysine may be, for example, about 0.01 to 6% by mass. The upper or lower limit of this range may be, for example, about 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, or 5.5% by mass. Specifically, it may be about 0.02 to 5.5% by mass.

[0045] The plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure may contain other ingredients as long as the effects of the present disclosure are not impaired. Examples of such other ingredients include pharmacologically or food hygienically acceptable solvents, dispersants, emulsifiers, buffers, stabilizers, excipients, binders, disintegrants, lubricants, thickeners, surfactants, antioxidants, preservatives, coating agents, colorants, and fragrances. These ingredients may be used alone or in combination of two or more.

[0046] Examples of the solvent include hydrophilic solvents such as water, and lipophilic solvents such as synthetic oils and fats such as medium-chain fatty acid triglycerides, vegetable oils and fats, and animal oils and fats. These components can be used alone or in combination of two or more.

[0047] The plasmalogen and ginkgo leaf extract-containing composition of the present disclosure can be prepared by a conventional method, for example, by combining plasmalogen, ginkgo leaf extract, and arginine and / or lysine, and optionally other ingredients.

[0048] Furthermore, the plasmalogen and ginkgo leaf extract-containing composition of the present disclosure can be preferably used, for example, in the production of pharmaceuticals or foods.

[0049] The plasmalogen- and ginkgo leaf extract-containing composition of the present disclosure is preferably used so that the plasmalogen intake per meal is 0.5 to 2.0 mg. The upper or lower limit of this range may be, for example, about 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, or 1.9 mg. Specifically, it may be about 0.6 to 1.9 mg.

[0050] In this specification, the term "comprising" includes "consisting essentially of" and "consisting of." In addition, the present disclosure includes any and all combinations of the constituent elements described in this specification.

[0051] Furthermore, the various characteristics (properties, structures, functions, etc.) described in each embodiment of the present disclosure above may be combined in any way to specify the subject matter encompassed by the present disclosure, i.e., the present disclosure encompasses all subject matter consisting of any combination of the combinable characteristics described herein. [Example]

[0052] The contents of the present disclosure will be specifically explained using the following experimental examples. However, the present disclosure is not limited to these in any way. In the following, unless otherwise specified, experiments were conducted under atmospheric pressure and room temperature conditions. Furthermore, unless otherwise specified, "%" means "% by mass." Furthermore, the blending amount of each component listed in each table is also expressed in "% by mass" unless otherwise specified.

[0053] 1. Evaluation of the stability of Pls (plasmalogen) To evaluate the stability of Pls, a Pls and ginkgo leaf extract-containing composition (Table 1) and a Pls-containing composition (Table 2) were prepared according to the formulations shown in Tables 1 and 2. After mixing a medium-chain triglyceride, emulsifier, and antioxidant, the mixture was heated to 60°C to dissolve the ingredients uniformly. Pls extract, Ginkgo Biloba Extract C (Maruzen Pharmaceutical Co., Ltd., hydroethanolic extract of ginkgo leaves (flavonol glycoside content ≥ 24.0%, terpene lactone content ≥ 6.0%, ginkgolide B content ≥ 0.8%, and ginkgolic acid content ≤ 1 ppm)), and a pH adjuster (arginine or citric acid ground in a mortar) were added and mixed using a homogenizer. The resulting mixtures were stored in light-shielding bottles (headspace purged with nitrogen gas) at 40°C. Pls was added to each composition so that the Pls concentration in each composition was approximately 0.6 mg / 300 mg (approximately 0.2% by mass), calculated based on the Pls content of the Pls extract. For each composition, Pls was quantified and pH was measured initially, 2 weeks, 1 month, 2 months, 3 months, and 4 months after application. pH measurements were performed on compositions diluted 10 times by mass with ion-exchanged water. The Pls extract was prepared by the method described in JP 2019-142818 A (Patent Document 5). Specifically, lipids were extracted from FD chicken breast meat with ethanol and concentrated. The resulting concentrate was purified to obtain a phospholipid concentrate. The phospholipid concentrate was diluted with water or ethanol to meet the specified concentration (Pls content of 12.5% ​​by mass or more), and this was used as the Pls extract.

[0054] [Table 1]

[0055] [Table 2]

[0056] 2. Lipid Extraction Lipid extraction was performed using the Bligh & Dyer method. Lipid extraction was performed only on the samples in Table 1 (Pls and ginkgo leaf extract-containing compositions). Approximately 0.4 g of sample was weighed into a Teflon (registered trademark) centrifuge bottle. 50 ml of chloroform, 50 ml of methanol, and 45 ml of 0.9% KCl were added, nitrogen gas was blown into the headspace, and the mixture was vigorously mixed by hand for 1 minute. The mixture was centrifuged at 3,000 rpm for 10 minutes at room temperature to separate the upper and lower layers. The lower layer was collected in an eggplant-shaped flask, and 50 ml of chloroform was added to the upper layer for re-extraction. The first and second lower layers were combined, concentrated using a rotary evaporator, and left overnight in a vacuum desiccator.

[0057] 3. Phospholipid Fractionation An appropriate amount of chloroform was added to the concentrate obtained in 2 above to dissolve it. Approximately 0.4 g of the sample (Pls-containing composition) in Table 2 was weighed out into a recovery flask, and an appropriate amount of chloroform was added, followed by concentration using a rotary evaporator. An appropriate amount of chloroform was added to the resulting concentrate to dissolve it. The concentrate dissolved in 6 ml of Mega BE-SI (Agilent Technologies), which had been washed with acetone and chloroform, was applied to the column, and the phospholipids were adsorbed onto the column. After washing the column with chloroform and acetone, the phospholipids were eluted with chloroform / methanol (2:1) and methanol and collected in a recovery flask. The collected phospholipids were concentrated using a rotary evaporator and allowed to stand in a vacuum desiccator for at least 30 minutes. The resulting concentrate was made up to volume in a 5 ml volumetric flask using chloroform / methanol (2:1). This was then filtered through a 0.2 μm filter to prepare the HPLC sample.

[0058] 4. Quantification of Phospholipids by HPLC Phospholipids in the HPLC samples were quantified using HPLC under the conditions shown in Tables 3 and 4. The Pls content in the analytical samples was calculated using a standard curve constructed from the peak areas of egg yolk-derived phosphatidylethanolamine (Sigma) and egg yolk-derived phosphatidylcholine (Sigma) with known concentrations.

[0059] [Table 3]

[0060] [Table 4]

[0061] The results of the stability evaluation of the samples in Table 1 (compositions containing Pls and ginkgo leaf extract) are shown in Figure 1. The initial Pls values ​​for each composition were almost the same as the expected values. After 2 weeks at 40°C, the amount of Pls in the unadjusted pH-treated samples was reduced compared to the samples without ginkgo leaf extract. On the other hand, in the compositions adjusted to pH 3.5 or higher, more Pls remained after 4 months at 40°C than in the samples without ginkgo leaf extract.

[0062] The results of the stability evaluation of the samples (Pls-containing compositions) in Table 2 are shown in Figure 2. The initial Pls values ​​for each composition were almost the same as expected. After 1 month at 40°C, the compositions adjusted to pH 3.5 or 4.0 had a reduced amount of Pls compared to the unadjusted pH composition. On the other hand, after 4 months at 40°C, the composition adjusted to pH 7.0 had more Pls remaining than the unadjusted pH composition.

[0063] The results of pH measurement for each composition are shown in Tables 5 and 6. Regardless of whether ginkgo biloba extract was present or not, when the pH of the composition was 4.8 or less, no change in pH was observed when stored at 40°C. However, the pH of the composition adjusted to pH 7.0 decreased. Normally, in the neutral range, a small amount of H + and OH -However, in the acidic and basic ranges, the pH does not fluctuate as much as in the neutral range. Therefore, it is thought that the pH decrease occurred only in the composition adjusted to pH 7.0.

[0064] [Table 5]

[0065] [Table 6]

[0066] A composition containing Pls and ginkgo leaf extract, and a composition containing Pls were prepared according to the formulations shown in Table 7. The Pls content and pH were measured at the initial stage and after 2 weeks at 40°C using the methods described above. The results are shown in Table 8.

[0067] [Table 7]

[0068] [Table 8]

[0069] When lysine was used, a stabilizing effect on plasmalogen was confirmed, whereas when histidine was used, no stabilizing effect was confirmed.

Claims

1. Plasmalogen, Ginkgo biloba extract, and containing arginine and / or lysine, The pH when diluted 10 times with ion-exchanged water is 3.4 to 5. composition.

2. The composition according to claim 1, wherein the plasmalogen intake per meal is 0.5 to 2.0 mg.

3. The composition according to claim 1 or 2, wherein the mass ratio of plasmalogen to ginkgo leaf extract is 1:8 to 1:

600.

4. The composition according to claim 1 or 2, containing 0.028 to 3.3% by mass of plasmalogen.

5. The composition according to claim 1 or 2, containing 4.44 to 75% by mass of ginkgo leaf extract.

6. The composition according to claim 1 or 2, which is a liquid composition.

Images